Pfizer signs licence agreement with Chai for AI drug discovery

Pfizer is betting that artificial intelligence can crack one of drug development's most stubborn problems: the staggering cost and time required to discover new medicines. The pharmaceutical giant's licensing agreement with Chai—a startup applying machine learning to molecular design—signals that even the industry's largest players see AI as essential to staying competitive, not optional. If the partnership yields faster, cheaper drug candidates, it could reshape the economics of an industry where a single blockbuster often takes a decade and billions of dollars to bring to market.

Pharmaceutical Technology·4d ago